Answers are grounded in this paper and cite their sources.
Background: Major depressive disorder (MDD) disproportionately affects people with chronic kidney disease (CKD) and is associated with non-adherence. We evaluated facilitators of and barriers to adherence to treatments for MDD among people with CKD. Methods: The CONCORD randomized controlled trial evaluated two treatment strategies vs. control for MDD in people with CKD G3b-5: Behavioral Activation Therapy (BAT) (plus placebo) or antidepressant bupropion (plus clinical management control) administered for 8 weeks, with escalation to a combination of BAT plus bupropion for another 8 weeks in those without MDD remission. The control arm received placebo and clinical management. BAT and clinical management were administered via video-teleconferencing. Focus groups were held virtually among study completers and one-on-one interviews among non-completers. The blinded allocation was kept concealed. An applied thematic analysis approach was used for data analysis using NVivo 15. Results: Fourteen focus groups (total N=52) and seven one-on-one interviews were conducted. The cohort was 58% women, 29% Black persons, and 31% Hispanic persons. Median (IQR) age was 59 (51, 64) years and mean (SD) estimated glomerular filtration rate was 27 (9) mL/min/1.73 m 2 . Adherence to study capsule by pill count was higher among focus group vs. one-on-one participants, but adherence to video-teleconferencing sessions was similar. Barriers to drug adherence included polypharmacy, large pill size, side effects attributed to study capsule, and forgetting to take medication. Facilitators of adherence included expectation of symptom improvement and desire to help others by knowledge gained. Participants reported a positive impact of participation on overall functioning and symptoms and indicated that skills learned in teletherapy were helpful. Some perceived video-teleconferencing sessions as more effective than medication, others attributed benefit to a combination of medication and video-teleconferencing, and a minority perceived medication as most effective. Conclusion: Facilitators of and barriers to treatment adherence can inform the management of MDD in people with CKD.
No takes yet. Share an insight, caveat, or question.
McAdams et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: